This is a snippet of the transcript, sign up to read more.
Yes. From memory, and I've not looked at both sets of results, I'm pretty sure that Essentra has got a higher retained margin than RS has, because there's more costs involved in the RS business, even though there's a manufacturing piece there in Essentra, but the manufacturing is a big part of Essentra's strength, and it makes them pretty unique as far as that marketplace is concerned.
This is a snippet of the transcript, sign up to read more.
Well MRO was different, they don't know what's going to break and when it's going to break. If you look at an MRO customer and you look, you took RS’s numbers, you would see that there'll be a 20% commonality of products that are bought last year to this year. The other 80% are different. And of that 80%, there's probably 50% of them that have never been bought before.
This is a snippet of the transcript, sign up to read more.
Essentra are a lot more stable because, typically, a manufacturer will go into making a product, and that product will last for a period of time, and sometimes that could be years. If you've got a bed manufacturer, for example, what the hell could Essentra sell them? Beds are sometimes still put on castors. Whether they would buy the castors from Essentra, I don't know. However, do you know when you used to get beds and there was a plastic metal screw on the back of it that you could drop the headboard in there, Essentra sell them and bed manufacturers buy them. There's probably a good commonality across lots of bed manufacturers that make headboards, they want to attach them to their beds to the plastic.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research